Zobrazeno 1 - 10
of 119
pro vyhledávání: '"C Hohberg"'
Autor:
M. Löbig, Thomas Forst, PB Musholt, Jürgen Müller, Ute Lehmann, Winfried Fuchs, Andreas Pfützner, Thomas Schöndorf, C. Hohberg
Publikováno v:
Journal of Diabetes Science and Technology. 5:426-432
Background: Type 2 diabetes mellitus (T2DM) is characterized by a proinflammatory and procoagulant condition. This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in compari
Autor:
Ute Lehmann, Jürgen Müller, A. Pfützner, Matthias M. Weber, Christiane Friedrich, C. Hohberg, Winfried Fuchs, Thomas Forst, M. Löbig
Publikováno v:
Clinical Science. 119:345-351
The aim of the present study was to compare the effect of PIO (pioglitazone) or GLIM (glimepiride) on erythrocyte deformability in T2DM (Type 2 diabetes mellitus). The study covered 23 metformin-treated T2DM patients with an HbA1c (glycated haemoglob
Publikováno v:
Journal of Diabetes Science and Technology. 4:976-982
Background: Continuous subcutaneous insulin infusion (CSII) by means of insulin pump devices is considered to be one of the most optimal therapies to achieve treatment targets in patients with diabetes mellitus. In CSII, the insulin is delivered thro
Publikováno v:
Diabetes, Obesity & Metabolism
AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin g
Autor:
Philip Pichotta, Senait Forst, Andreas Pfützner, C. Hohberg, Thomas Forst, Eda Tarakci, Solomon S. Steiner, Alan Krasner, Frank Flacke
Publikováno v:
Diabetes Care
OBJECTIVE Recent studies suggested an impact of prandial insulin delivery on postprandial regulation of tissue blood flow. This study compared the effect of VIAject with human regular insulin and insulin lispro on postprandial oxidative stress and en
Autor:
M. Borchert, A. Pfützner, Thomas Schöndorf, E. Karagiannis, C. Hohberg, Thomas Forst, Georg Lübben
Publikováno v:
Diabetes, Obesity and Metabolism. 11:464-471
AIM Insulin treatment is considered to be the final option for patients with progressive type 2 diabetes. This study investigated, whether reconverting type 2 patients from insulin treatment to oral treatment using pioglitazone is possible without de
Publikováno v:
Hormone and Metabolic Research. 41:123-131
The metabolic syndrome is associated with an excess of increase in cardiovascular complications. Disturbances in insulin efficacy and insulin secretion are major features of the metabolic syndrome and might precede the development of diabetes mellitu
Publikováno v:
Journal of Diabetes Science and Technology. 2:1151-1156
Background and Aims: Skin microvascular assessment has progressed to an important evaluation in patients with diabetes mellitus. This study was done to evaluate a new device using micro-lightguide spectrophotometry in the assessment of skin microvasc
Publikováno v:
Current Medical Research and Opinion. 24:2545-2549
The injection force and the patient perception of the Next Generation FlexPen (NGFP) with design modifications aimed at reducing injection force was assessed. The accuracy and precision of the NGFP was also tested under standard conditions.Dosing acc
Autor:
W. Dänschel, Andreas Pfützner, Gerhard Dikta, M. Morcos, Georg Lübben, E. Karagiannis, Thomas Forst, M. Drexler, C. Hohberg, Thomas Schöndorf, M. Borchert
Publikováno v:
Atherosclerosis. 197:311-317
We investigated MMP-9 levels and inflammatory markers during pioglitazone treatment in type 2 diabetic patients with cardiovascular disease. In this randomized multicenter, double blinded, placebo controlled study, 92 type 2 diabetic patients with an